Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Liposarcoma 1

Interventions

Doxorubicin 4pembrolizumab 3Specimen Handling 3toripalimab 2Ifosfamide 2Biopsy 2silmitasertib 1selinexor 1peposertib 1pemigatinib 1pazopanib 1palbociclib 1mirdametinib 1liposomal doxorubicin 1abemaciclib 1X-Rays 1Vincristine 1Trabectedin 1Temozolomide 1Surgical Procedures, Operative 1Radiotherapy 1Quality of Life 1Proton Therapy 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Irinotecan 1Injections 1Histamine H2 Antagonists 1Gemcitabine 1Famotidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Liposarcoma × silmitasertib × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡